Key facts
- It has raised $109.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($109.0M) in Dec 2025.
- Notable investors include RA Capital Management, Catalio Capital Management, CVX Ventures, Forbion, Samsara BioCapital — 6 tracked in total.
- 1 investment vehicle was formed to buy Sidera shares in the last 12 months, reporting $338K sold to 5 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Sidera
Funding rounds
1 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Sidera shares, reporting $338K sold to 5 investors. Most recent filing Jun 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Sidera
Developer of a genetic research platform designed to study disease mechanisms using human genetics. The company provides genetic analysis tools to identify genes associated with disease susceptibility and protection, enabling healthcare organizations to develop personalized medicine approaches and translate genetic data into practical health applications.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2023
- Employees
- 6
- Website
- siderabio.com/
- Ownership
- Privately Held (backing)
Sidera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sidera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sidera in its N-PORT filings yet. We sweep new filings monthly.